Drug Profile
AAA 817
Alternative Names: 225 Actinium PSMA 617; 225 Actinium PSMA 617 - Novartis; 225Ac PSMA 617; AAA-817; Ac-225-PSMA-617Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Endocyte
- Developer Endocyte; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 01 Apr 2021 Phase-I clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in Australia (Parenteral) (NCT04597411)
- 01 Apr 2021 Phase-I clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in South Africa (Parenteral)(NCT04597411)
- 26 Oct 2020 Endocyte plans a phase I trial for Prostate cancer (Metastatic disease, Hormone refractory) in November 2020 (NCT04597411)